SGTX News and Press, Sigilon Therapeutics Inc. From 07/12/21

Gainers: Tempest Therapeutics (TPST) +98%, Xtant Medical (XTNT) +31%, Celldex Therapeutics CLDX +29%, SCWorx (WORX) +20%, ReShape Lifesciences (RSLS) +12%.Losers: Sigilon Therapeutics (SGTX) -9%, TransMedics (TMDX) -8%, Prothena PRTA...

naphtalina/iStock via Getty Images COVID-19-related headlines dominated the holiday-shortened week as the Delta variant of the virus renewed pandemic fears across the globe. Meanwhile, with a ~1.3% gain over the past five-day period, the S&P 500 Healthcare Index outper...

Biotechnology start-up Sigilon Therapeutics (NASDAQ: SGTX) is getting beaten down after announcing a clinical hold for its experimental hemophilia drug. Investors worried testing might not resume hammered shares of the clinical-stage biotech stock 23.4% lower as of 12:55 p.m. EDT on...

Gainers: SGOCO Group (SGOC) +250%.Stamps.com STMP +64%.ToughBuilt Industries TBLT +48%.Carver Bancorp CARV +39%.Galectin Therapeutics GALT +33%.Tempest Therapeutics (TPST) +20%.Sequential Brands Group (SQBG) +19%.LMP Automotive LMPX +18%.Grupo Simec, S.A.B. de C.V. (S...

Gainers: Galectin Therapeutics GALT +40%, ReShape Lifesciences (RSLS) +21%, INmune Bio (INMB) +17%, ASLAN Pharmaceuticals (ASLN) +15%, 89bio (ETNB) +14%.Losers: Sigilon Therapeutics SGTX -30%, Aerpio Pharmaceuticals (ARPO) -14%, Alterity ...

The U.S. FDA has placed a clinical hold on Sigilon Therapeutics' (SGTX) Phase 1/2 study of SIG-001 in patients with severe or moderately severe hemophilia A.The clinical hold was initiated following the company’s submission of a serious adverse event ((SAE)) and temporary enrollme...

CAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported that the U.S. Food and Drug Administrat...

CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the appointment of Brooke Story to its...

Sigilon Therapeutics (SGTX) announces the appointment of Philip Ashton-Rickardt as the company's chief scientific officer ((CSO)).Most recently, Ashton-Rickardt served as Senior Vice President for Immunology at AZTherapies.At AZTherapies, he was responsible for preclinical development of cell...

CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the appointment of Philip Ashton-Ricka...